654
References
Adida B, Kohane IS. GenePING: secure, scalable management of personal genomic data. BMC
Genomics. 2006;7:93.
Blumenthal D, Tavenner M. The “meaningful use” regulation for electronic health records. N Engl
J Med. 2010;363:501–4.
Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–5.
Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions.
Cell. 2012;148:409–20.
DesRoches CM, Campbell EG, Rao SR, et al. Electronic health records in ambulatory care – a
national survey of physicians. NEJM. 2008;359:50–60.
Downing GJ, Boyle SN, Brinner KM, Osheroff JA. Information management to enable personal-
ized medicine: stakeholder roles in building clinical decision support. BMC Med Inform Decis
Mak. 2009;9:44.
Fries S, Grosser T, Price TS, et al. Marked interindividual variability in the response to selective
inhibitors of cyclooxygenase-2. Gastroenterology. 2006;130:55–64.
Haga SB, LaPointe NM. The potential impact of pharmacogenetic testing on medication adher-
ence. Pharmacogenomics J. 2013;13:481–3.
Hamburg MA, Collins FS. The path to personalized medicine. NEJM. 2010;363:301–4.
Hudson KL. Genomics, health care, and society. N Engl J Med. 2011;365:1033–41.
Jha AK, DesRoches CM, Campbell EG, et al. Use of electronic health records in U.S. hospitals.
NEJM. 2009;360:1628–38.
Kellermann AL, Jones SS. What it will take to achieve the as-yet-unfulfi lled promises of health
information technology. Health Aff. 2013;32:63–8.
Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting hetero-
geneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85.
Kho AN, Pacheco JA, Peissig PL, et al. Electronic medical records for genetic research: results of
the eMERGE consortium. Sci Transl Med. 2011;3:79re1.
Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. JAMA.
2006;296:212–5.
Lai TL, Lavori PW, Shih MC, Sikic BI. Clinical trial designs for testing biomarker-based personal-
ized therapies. Clin Trials. 2012;9:141–54.
Mooser V, Currat C. The Lausanne Institutional Biobank: a new resource to catalyse research in
personalised medicine and pharmaceutical sciences. Swiss Med Wkly. 2014;144:w14033.
Moynihan R, Henry D, Moons KG. Using evidence to combat overdiagnosis and overtreatment:
evaluating treatments, tests, and disease defi nitions in the time of too much. PLoS Med.
2014;11:e1001655.
Scheuner MT, de Vries H, Kim B, et al. Are electronic health records ready for genomic medicine?
Genet Med. 2009;11:510–7.
Simon R. Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and com-
panion diagnostics. Exp Opin Med Diagn. 2008;2:721–9.
Stachnik A, Yuen T, Iqbal J, et al. Repurposing of bisphosphonates for the prevention and therapy
of nonsmall cell lung and breast cancer. Proc Natl Acad Sci U S A. 2014;111:17995–8000.
Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitu-
mor effects in p53-defi cient human colon tumor xenografts. Proc Natl Acad Sci U S A.
2006;103:11003–8.
Wing K, Douglas I, Bhaskaran K, et al. Development of predictive genetic tests for improving the
safety of new medicines: the utilization of routinely collected electronic health records. Drug
Discov Today. 2014;19:361–6.
Yang JY, Yang MQ, Zhu MM, et al. Promoting synergistic research and education in genomics and
bioinformatics. BMC genomics 2008;9 Suppl 1:I1.
Yao L, Zhang Y, Li Y, et al. Electronic health records: implications for drug discovery. Drug
Discov Today. 2011;16:594–9.
20 Development of Personalized Medicine